Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura

Acta Haematologica

Volumn 115, Issue 1-2, 2006, Pages 46-52

  El Alfy, Mohsen S ^a   Mokhtar, Galila M ^a   El Laboudy, Mohamed A M ^a   Khalifa, Ahmed Samy ^a,b  

^a Ain Shams University   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Anti D immunoglobulin; Bleeding episodes; Idiopathic thrombocytopenic purpura; Immunoglobulin; Intravenous immunoglobulin; Platelet count; Splenectomy

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN; RHESUS D ANTIBODY; VIGAM S; WIN RHO;

ADOLESCENT; ARTICLE; BLEEDING; BLOOD CELL COUNT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTRAVASCULAR HEMOLYSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MENINX DISORDER; MUSCULOSKELETAL PAIN; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; RETICULOCYTE COUNT; RETICULOCYTOSIS; RISK ASSESSMENT; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; RETICULOCYTE COUNT; RHO(D) IMMUNE GLOBULIN;

EID: 31144479365     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089465     Document Type: Article

References (31)

1. Milewska RR, Zupoanska B, Obikto-Pludowska A, Sulkowski G, Namirska-Krzton H: Intravenous immunoglobulin anti-D treatment of chronic immune thrombocytopenic purpura in children. Int J Pediatr Hematol Oncol 1996; 3:433-438.
2. Blanchette V: Childhood chronic immune thrombocytopenic purpura. Blood Rev 2002;16:23-26.
3. Lichtin A: The ITP practice guideline: what, why, and for whom? Blood 1996;88:1-2.
4. Malinowska I, Obitko-Pludowska A, Buescher ES, Wasik M, Milewska RR: Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J 2001;2:242-249.
5. Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, Gent M: A prospective randomized trial of high-dose intravenous immunoglobulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993;123:989-995.
6. Bolton-Maggs PH, Moon I: Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines. Lancet 1997;350:620-623.
7. Ballow M: Mechanisms of action of intravenous immune serum globulin therapy. Pediatr Infect Dis J 1994;13:806-811.
8. Aukrust P, Froland SS, Liabakk N, Muller F, Nordoy I, Haug C, Espevik T: Release of cytokines, soluble cytokine receptors and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-2143.
9. Scaradavou A, Woo B, Woloski BMR, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB: Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997;89:2689-2700.
10. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, Miller R, Ali K, Bernard D, Chan KW, Esseltine D, De Veber B, Kobrinosky N, Luke B: Randomised trial of intravenous immunoglobulin G, intravenous anti-D and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344:703-707.
11. Bussel J: Novel approaches to the management of immune thrombocytopenic purpura: results of recent trails. 43rd Annual Meeting of the American Society of Hematology, Orlando, December 7-11, 2001, pp 288-300.
12. Bussel JB, Pham LC: Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987;52:206-211.
13. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82:1415-1421.
14. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort L: Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity and mechanism of effect. Blood 1991;77:1884-1893.
15. Scaradavou A, Bussel JB: Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura. Semin Hematol 1998;35:52-57.
16. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB: A dose of 75 μg/ kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura. Br J Hematol 2001;112: 1076-1078.
17. Albayrak D, Islek I, Kalayci AG, Gurses N: Acute immune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and intravenously administered immune globulin. J Pediatr 1994;125: 1004-1007.
18. Ancona KG, Parker RI, Atlas MP, Prakash D: Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2002;24:540-544.
19. Newland AC, Burton I, Cavenagh JD, Copplestone A, Dolan G, Houghton J, Reilly T: Vigam-S, a solvent/detergent-treated intravenous immunoglobulin in idiopathic thrombocytopenic purpura. Transfus Med 2001;11:37-44.
20. Sandler SG, Norak SC, Rolond B: The cost of treating immune thrombocytopenic purpura using intravenous Rh immunoglobulin versus intravenous immunoglobulin. Am J Hematol 2000;63:156-158.
21. Khalifa AS, Tolba KA, El-Alfy MS, Gadallah M, Ibrahim FI: Idiopathic thrombocytopenic purpura in Egyptian children. Acta Hematol 1993;90:125.
22. Warrier I: The Low-Dose IVIG Study Group: Safety and efficacy of low-dose intravenous immunoglobulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura (ITP). J Pediatr Hematol Oncol 1997;19:197-201.
23. Lee KS: Low dose and short-term therapy of intravenous immunoglobulin for childhood acute immune thrombocytopenic purpura (in Korean). Korean J Hematol 2001;36:247-252.
24. Blanchette V, Carcao M: Approach to the investigation and management of immune thrombocytopenic purpura in children. Semin Hematol 2000;37:299-314.
25. Cooper N, Woloski MR, Fodero EM, Novoa M, Leber M, Beer JH, Bussel JB: Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood 2002;99: 1922-1927.
26. Jayabose S, Mahmoud M, Levendoglu-Tugal O: Corticosteroid prophylaxis for neurologic complications of IVIG therapy in childhood immunothrombocytopenic purpura. J Pediatr Hematol Oncol 1999;21:514-517.
27. Scribner CL, Kapit RM, Phillips ET: Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994;121:305-306.
28. Kattamis AC, Shankar S, Cohen A: Neurologic complications of treatment of childhood immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997;130:281-283.
29. Bennet CL, Weinberg PD, Golub RM, Bussel JB: The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis. Semin Hematol 2000;37(suppl 1):26-30.
30. Waintraub SE, Brody JI: Use of anti-D in immune thrombocytopenic purpura as a means to prevent splenectomy: case reports from two university hospital medical centers. Semin Hematol 2000;37(1 suppl 1):45-49.
31. Buchanan GR, Di Paola JA: Immune thrombocytopenic purpura. Pediatr Clin North Am 2002;49:911-928.